CD19 and B-cell non-Hodgkin lymphoma: In this study, we evaluated the incidence and clinical impact of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (ADV) reactivations in 75 patients receiving anti-BCMA CAR-T for MM, and compared them to 60 patients receiving commercial anti-CD19 CAR-T for B-cell lymphoma (BCL).